Radiology devices branch on the move
This article was originally published in The Gray Sheet
Executive Summary
FDA's Radiological Devices Branch is moving from its current home in the Office of Device Evaluation to the Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), FDA says. One of the center's largest review branches, the radiological devices office encompasses diagnostic devices such as x-ray and magnetic resonance imaging equipment, as well as non-diagnostic products such as radiofrequency ablation catheters and cancer radiation treatments. The branch is expected to retain its current personnel, according to a member of the Radiological Society of North America
You may also be interested in...
Radiology Devices Move To OIVD: More Cohesive Dx Reviews Ahead?
FDA hopes that shuttling its Radiological Devices Branch to the Office of In Vitro Diagnostic Device Evaluation and Safety will produce more cohesive policies on diagnostic device review
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.